

A: HGHAX **C:** HGHGX **F:** HGHFX **I:** HGHIX **R3:** HGHXR **R4:** HGHXS **R5:** HGHXT **R6:** HGHVX **Y:** HGHYX

Objective Seeks long-term capital appreciation.

Inception Date 5/01/00 **Morningstar Category** Health

Opportunistic

Seeks to capitalize on the demographics, globalization, and innovation opportunities in the global-health care market

Best Ideas

Uses in-depth research to create a portfolio with the best ideas from portfolio managers and analysts

Sub-advised by Wellington

Wellington prioritizes independent thought and collaboration across all major asset classes

Average Annual Total Returns (%)

Class	QTD	YTD	1 Year	3 Year	5 Year	10 Year	SI
I	0.66	0.66	-6.11	0.18	7.77	6.56	10.40
F	0.68	0.68	-6.02	0.28	7.87	6.64	10.43
A	0.57	0.57	-6.34	-0.09	7.48	6.27	10.15
A with 5.5% Max Sales Charge	—	—	-11.49	-1.95	6.27	5.67	9.91
Benchmark	5.54	5.54	-0.13	3.29	11.91	9.02	—
Morningstar Category	-1.46	-1.46	-6.28	-1.28	6.84	5.31	—

Share Class Inception: A - 5/1/00; F - 2/28/17; I - 8/31/06. Performance shown prior to the inception of a class reflects performance and operating expenses of another class(es) (excluding sales charges, if applicable). Had fees and expenses of a class been reflected for the periods prior to the inception of that class, performance would be different. Since inception (SI) performance is from 5/1/00. Performance and expenses for other share classes will vary. Additional information is in the prospectus. Only Class A assesses a sales charge. Performance for periods of less than one year is not annualized.

Benchmark: S&P Composite 1500 Health Care Index comprises those companies included in the S&P Composite 1500 that are classified as members of the GICS health care sector. Indices are unmanaged and not available for direct investment.

Portfolio managers from Wellington Management and years of experience

Rebecca Sykes, CFA, 20 years
Wen Shi, CFA, 18 years
David Khtikian, CFA, 26 years
Samuel Bitetti, CFA, 18 years

Expenses (%)


	I	F	A
Gross	1.02	0.92	1.29
Net	1.02	0.92	1.29

Expenses are the total annual operating expenses from the Fund's most recent prospectus at the time of publication.

Calendar Year Returns (%)

2024	0.25
2023	4.06
2022	-11.48
2021	10.24
2020	22.91
2019	33.69
2018	-2.74
2017	21.94
2016	-8.33
2015	12.97

Value of a \$10,000 Investment (Class I)



Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted. For more current performance information to the most recent month ended, please visit hartfordfunds.com.

Investors should carefully consider a fund's investment objectives, risks, charges and expenses. This and other important information is contained in a fund's full prospectus and summary prospectus, which can be obtained by visiting hartfordfunds.com. Please read it carefully before investing.

Mutual funds are distributed by Hartford Funds Distributors, LLC (HFD), Member FINRA. Advisory services are provided by Hartford Funds Management Company, LLC (HFMC). Certain funds are sub-advised by Wellington Management Company LLP. HFMC and Wellington Management are SEC registered investment advisers. HFD and HFMC are not affiliated with any sub-adviser.

Subsector Exposure (%)

	Fund	Benchmark	Underweight/Overweight
Biopharma Mid Cap	10	3	7
Health Care Services	27	23	4
Biopharma Small Cap	2	0	2
Medical Technology	25	30	-5
Biopharma Large Cap	36	44	-8

Based on sub-adviser's classification of health care subsectors, which includes combining biotechnology and pharmaceuticals in terms of capitalization: biopharma small-cap, biopharma mid-cap, and biopharma large-cap. Excludes cash. May not total to 100% due to rounding.

Top Ten Holdings (%)

Eli Lilly & Co.	13.05
UnitedHealth Group, Inc.	10.08
Boston Scientific Corp.	4.76
Merck & Co., Inc.	3.94
Intuitive Surgical, Inc.	3.39
Vertex Pharmaceuticals, Inc.	2.96
Thermo Fisher Scientific, Inc.	2.79
Johnson & Johnson	2.54
Cencora, Inc.	2.51
AbbVie, Inc.	2.45
Percentage Of Portfolio	48.47

Fund Characteristics

Net Assets	\$903 million
# of Holdings	100
% in Equities	100%
% in Foreign Equities	11%
Beta (3 yrs)	1.01
R Squared (3 yrs)	0.93
Standard Deviation (3 yrs)	14.52%
Turnover	43%

Holdings Characteristics

	Fund	Benchmark
Price/Earnings	22.5x	15.8x
Price/Book	5.0x	4.8x
EPS Growth Rate	11.1%	10.2%
Return on Equity	20.4%	32.7%
Asset Weighted Market Cap (billions)	\$230.1	\$254.6
Median Market Cap (billions)	\$6.6	\$6.3

Market Cap Distribution (%)

Less than \$2 billion	4
\$2 billion - \$5 billion	8
\$5 billion - \$10 billion	7
Greater than \$10 billion	81
Not Classified	0

Benchmark S&P Composite 1500 Health Care Index

Holdings and characteristics are subject to change. Percentages may be rounded.

Important Risks: Investing involves risk, including the possible loss of principal. Security prices fluctuate in value depending on general market and economic conditions and the prospects of individual companies. • Risks of focusing investments on the healthcare related sector include regulatory and legal developments, changes in funding or subsidies, patent and intellectual property considerations, intense competitive pressures, rapid technological changes, long and costly process for obtaining product approval by government agencies, potential product obsolescence, rising cost of medical products and services, and price volatility risk. • Small- and mid-cap securities can have greater risks and volatility than large-cap securities. • The securities of large market capitalization companies may underperform other segments of the market. • Foreign investments may be more volatile and less liquid than U.S. investments and are subject to the risk of currency fluctuations and adverse political, economic and regulatory developments.

Beta measures the volatility of a portfolio relative to a benchmark. A beta of less than 1.00 indicates lower risk than the market; a beta of greater than 1.00 indicates higher risk than the market. **R Squared** represents the percentage of the portfolio's movement that can be explained by the market. **Standard Deviation** measures the portfolio's total-return volatility. A higher standard deviation indicates greater historical volatility. **Turnover** is a measure of the Fund's trading activity which represents the portion of the Fund's holdings that has changed over a twelve-month period through the Fund's fiscal year end. Turnover shown excludes To-Be-Announced roll transactions, if any. **Price/Earnings** is the ratio of a stock's price to its earnings per share. **Price/Book** is the ratio of a stock's price to its book value per share. **EPS Growth Rate** is the projected growth rate in earnings per share for the next five years. **Return on Equity** is the average amount of net income returned as a percentage of shareholder's equity over the past five years. **Asset Weighted Market Cap** is the value of a corporation as determined by the number of outstanding shares of common stock multiplied by the price per share.